PTDSS1
PTDSS1 catalyzes the formation of phosphatidylserine from either phosphatidylcholine or phosphatidylethanolamine. Phosphatidylserine localizes to the mitochondria-associated membrane of the endoplasmic reticulum, where it serves a structural role as well as a signaling role. Defects in this gene are a cause of Lenz-Majewski hyperostotic dwarfism.
Full Name
Phosphatidylserine synthase 1
Function
Catalyzes a base-exchange reaction in which the polar head group of phosphatidylethanolamine (PE) or phosphatidylcholine (PC) is replaced by L-serine (PubMed:19014349, PubMed:24241535).
Catalyzes mainly the conversion of phosphatidylcholine (PubMed:19014349, PubMed:24241535).
Also converts, in vitro and to a lesser extent, phosphatidylethanolamine (PubMed:19014349, PubMed:24241535).
Catalyzes mainly the conversion of phosphatidylcholine (PubMed:19014349, PubMed:24241535).
Also converts, in vitro and to a lesser extent, phosphatidylethanolamine (PubMed:19014349, PubMed:24241535).
Biological Process
Phosphatidylserine biosynthetic processManual Assertion Based On ExperimentIDA:FlyBase
Involvement in disease
Lenz-Majewski hyperostotic dwarfism (LMHD):
A syndrome of intellectual disability and multiple congenital anomalies that features generalized craniotubular hyperostosis. LMHD is characterized by the combination of sclerosing bone dysplasia, intellectual disability and distinct craniofacial, dental, cutaneous and distal limb anomalies. The progressive generalized hyperostosis associated with this syndrome affects the cranium, the vertebrae and the diaphyses of tubular bones, leading to severe growth restriction.
A syndrome of intellectual disability and multiple congenital anomalies that features generalized craniotubular hyperostosis. LMHD is characterized by the combination of sclerosing bone dysplasia, intellectual disability and distinct craniofacial, dental, cutaneous and distal limb anomalies. The progressive generalized hyperostosis associated with this syndrome affects the cranium, the vertebrae and the diaphyses of tubular bones, leading to severe growth restriction.
Topology
Cytoplasmic: 2-35
Helical: 36-56
Lumenal: 57-72
Helical: 73-93
Cytoplasmic: 94-102
Helical: 103-123
Lumenal: 124-186
Helical: 187-207
Cytoplasmic: 208-216
Helical: 217-237
Lumenal: 238-286
Helical: 287-307
Cytoplasmic: 308-319
Helical: 320-342
Cytoplasmic: 343-355
Helical: 356-376
Lumenal: 377-383
Helical: 384-404
Cytoplasmic: 405-473
Helical: 36-56
Lumenal: 57-72
Helical: 73-93
Cytoplasmic: 94-102
Helical: 103-123
Lumenal: 124-186
Helical: 187-207
Cytoplasmic: 208-216
Helical: 217-237
Lumenal: 238-286
Helical: 287-307
Cytoplasmic: 308-319
Helical: 320-342
Cytoplasmic: 343-355
Helical: 356-376
Lumenal: 377-383
Helical: 384-404
Cytoplasmic: 405-473
View more
Anti-PTDSS1 antibodies
+ Filters

Target: PTDSS1
Host: Mouse
Antibody Isotype: IgG
Specificity: Human, Mouse, Rat
Clone: B-5
Application*: WB, IP, IF, E
More Infomation
Hot products 
For Research Use Only. Not For Clinical Use.
(P): Predicted
* Abbreviations
- AActivation
- AGAgonist
- APApoptosis
- BBlocking
- BABioassay
- BIBioimaging
- CImmunohistochemistry-Frozen Sections
- CIChromatin Immunoprecipitation
- CTCytotoxicity
- CSCostimulation
- DDepletion
- DBDot Blot
- EELISA
- ECELISA(Cap)
- EDELISA(Det)
- ESELISpot
- EMElectron Microscopy
- FFlow Cytometry
- FNFunction Assay
- GSGel Supershift
- IInhibition
- IAEnzyme Immunoassay
- ICImmunocytochemistry
- IDImmunodiffusion
- IEImmunoelectrophoresis
- IFImmunofluorescence
- IHImmunohistochemistry
- IMImmunomicroscopy
- IOImmunoassay
- IPImmunoprecipitation
- ISIntracellular Staining for Flow Cytometry
- LALuminex Assay
- LFLateral Flow Immunoassay
- MMicroarray
- MCMass Cytometry/CyTOF
- MDMeDIP
- MSElectrophoretic Mobility Shift Assay
- NNeutralization
- PImmunohistologyp-Paraffin Sections
- PAPeptide Array
- PEPeptide ELISA
- PLProximity Ligation Assay
- RRadioimmunoassay
- SStimulation
- SESandwich ELISA
- SHIn situ hybridization
- TCTissue Culture
- WBWestern Blot

Online Inquiry